Chen S S, Lee L
Gynecol Oncol. 1983 Aug;16(1):95-100. doi: 10.1016/0090-8258(83)90013-6.
In patients with ovarian carcinoma, the presence of metastatic disease in a retroperitoneal lymph node is indicative of a poor prognosis. Although a "staging laparotomy" is required for proper treatment, definitive information concerning para-aortic and pelvic lymph node metastasis often is not available. To determine the incidence of retroperitoneal lymph node metastases in untreated cases of ovarian carcinoma, a prospective study by selective nodal biopsy was undertaken in 61 unselected patients with the following distribution: Stage I, 11; Stage II, 10; Stage III, 31; and Stage IV, 9. The incidence of para-aortic node metastasis overall was 37.7% and of pelvic node metastasis, 14.8%. Of 23 patients with positive para-aortic nodes, 30.4% had no concomitant pelvic node involvement. Direct relationships between nodal metastasis and clinical stage, tumor grade, and histologic type of tumor were demonstrated. The incidence of positive para-aortic nodes in Stage I disease was 18.2%; in Stage II, 20.0%; in Stage III, 41.9%; and in Stage IV, 66.7%. The corresponding incidence of pelvic node metastasis was 9.1% in Stage I, 10.0% in Stage II, 12.9% in Stage III, and 33.3% in Stage IV. Grade 3 tumors were associated most frequently with nodal involvement, with an incidence of positive para-aortic nodes of 52.5% and of positive pelvic nodes of 15.5%. In patients with a serous type of malignancy, the frequencies of positive para-aortic/pelvic nodes were 44.4%/16.7%, respectively; in the undifferentiated type, 50.0%/10.0%; in the clear cell type, 25.0%/25.0%; and in the mucinous type, 14.3%/14.3%. In this small series, 32 patients (52.5%) had positive retroperitoneal nodal involvement. It is concluded that selective biopsies of the para-aortic and pelvic lymph nodes should be part of any "staging laparotomy" for ovarian carcinoma, and that the true incidence of nodal involvement in these patients awaits further investigation.
在卵巢癌患者中,腹膜后淋巴结出现转移性疾病提示预后不良。尽管恰当的治疗需要进行“分期剖腹术”,但关于腹主动脉旁和盆腔淋巴结转移的确切信息往往无法获得。为了确定未经治疗的卵巢癌病例中腹膜后淋巴结转移的发生率,对61例未经挑选的患者进行了一项选择性淋巴结活检的前瞻性研究,其分期分布如下:I期11例;II期10例;III期31例;IV期9例。腹主动脉旁淋巴结转移的总体发生率为37.7%,盆腔淋巴结转移的发生率为14.8%。在23例腹主动脉旁淋巴结阳性的患者中,30.4%没有同时合并盆腔淋巴结受累。研究证实了淋巴结转移与临床分期、肿瘤分级和肿瘤组织学类型之间的直接关系。I期疾病中腹主动脉旁淋巴结阳性的发生率为18.2%;II期为20.0%;III期为41.9%;IV期为66.7%。盆腔淋巴结转移的相应发生率在I期为9.1%,II期为10.0%,III期为12.9%,IV期为33.3%。3级肿瘤最常与淋巴结受累相关,腹主动脉旁淋巴结阳性的发生率为52.5%,盆腔淋巴结阳性的发生率为15.5%。在浆液性恶性肿瘤患者中,腹主动脉旁/盆腔淋巴结阳性的频率分别为44.4%/16.7%;未分化型中为50.0%/10.0%;透明细胞型中为25.0%/25.0%;黏液型中为14.3%/14.3%。在这个小系列研究中,32例患者(52.5%)有腹膜后淋巴结受累阳性。得出的结论是,腹主动脉旁和盆腔淋巴结的选择性活检应成为任何卵巢癌“分期剖腹术”的一部分,并且这些患者中淋巴结受累的真实发生率有待进一步研究。